000			03257cam a2200349 a 4500
003			EG-GiCUC
005			20250223031512.0
008			160522s2015 ua d f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aPh.D
099			_aCai01.08.09.Ph.D.2015.Ma.P
100	0		_aMagy Refaat Nasry
245	1	0	_aPossible modification of pharmacological effects of pioglitazone by certain antioxidants in metabolic syndrome induced in rats / _cMagy Refaat Nasry ; Supervised Ezz Eldin Eldenshary ,Hala Fahmy Zaki , Amira Mourad Abo-Youssef
246	1	5	_aاحتمال تغيير تاثيرات فارماكولوجية للبيوجليتازون باستخدام بعض مضادات الاكسدة فى الجرذان المصابة بمتلازمة الايض
260			_aCairo : _bMagy Refaat Nasry , _c2015
300			_a221 P. : _bcharts ; _c25cm
502			_aThesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmacology and Toxicology
520			_aObjective: Incidence of metabolic syndrome (MS) is strongly associated with increased fructose consumption. This study aimed to elucidate the role of pioglitazone, Ü-lipoic acid, hesperidin, caffeic acid and their combinations on fructose-induced MS. Materials and methods: Theriteen groups of rats (n=8) were used. Groups 1-5 were fed on normal diet. First group served as normal control, and the remaining received pioglitazone (2.7 mg/kg), Ü-lipoic acid (100 mg/kg), hesperidin (50 mg/kg) and caffeic acid (20 mg/kg), respectively. Groups 6-13 were fed on fructose-enriched diet (FED) for 15 weeks. The 6th group served as positive control group, and the remaining groups received pioglitazone (2.7 mg/kg), Ü-lipoic acid (100 mg/kg), combination of pioglitazone and Ü-lipoic acid, hesperidin (50 mg/kg), combination of pioglitazone and hesperidin, caffeic acid (20 mg/kg) and combination of pioglitazone and caffeic acid, respectively. Treatments started 10 weeks after the beginning of fructose feeding. At the end of the study, blood and tissue samples were collected for estimation of MS-related markers. Results: Induction of MS was associated with increased weight gain and insulin resistance coupled with elevated levels of blood glucose, insulin, uric acid, urea, creatinine and lipids as well as activities of liver transaminases. FED also reduced glutathione peroxidase activity and total antioxidant capacity, increased nitric oxide and lipid peroxides contents parallel to increased serum levels of leptin and tumor necrosis factor-alpha. Treatment with pioglitazone, Ü-lipoic acid, hesperidin or caffeic acid attenuated most of the changes associated with MS. Besides, combinations of pioglitazone with any of tested agents further improved disease markers
530			_aIssued also as CD
653		4	_aMetabolic syndrome
653		4	_aPioglitazone
653		4	_aÜ-lipoic acid
700	0		_aAmira Mourad Abo-Youssef , _eSupervisor
700	0		_aEzz Eldin Eldenshary , _eSupervisor
700	0		_aHala Fahmy Zaki , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aAml _eCataloger
905			_aNazla _eRevisor
942			_2ddc _cTH
999			_c56587 _d56587